title: Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
abstract: BACKGROUND
  Ipilimumab is a fully human monoclonal antibody (mAb) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Ipilimumab is currently approved in the U.S. and Europe for the treatment of metastatic melanoma in the first- and second-line treatment. Treatment with ipilimumab is linked to immune-related adverse events (irAEs) occurring in the majority of patients. These specific AEs include dermatitis, gastrointestinal disorders (diarrhea, colitis), hepatitis, hypophysitis, hypothyroidism, neuropathy, and iritis/inflammation of the ciliary body.
  
  
  METHODS
  We report a case of febrile neutropenia with agranulocytosis in the blood smear of a 35-year-old metastatic melanoma patient treated with ipilimumab 3 mg/kg.
  
  
  CONCLUSIONS
  This AE was probably caused by antineutrophil antibodies associated with ipilimumab treatment. To our knowledge this is the first case report of febrile neutropenia in a metastatic melanoma patient treated with ipilimumab 3 mg/kg.
authors: Department of Chemotherapy, Greater Poland Cancer Centre, Poznan, Poland.
authors: Sebastian
authors: S
authors: Woźniak
authors: Małgorzata
authors: M
authors: Mackiewicz-Wysocka
authors: Łukasz
authors: Ł
authors: Krokowicz
authors: Łukasz
authors: Ł
authors: Kwinta
authors: Jacek
authors: J
authors: Mackiewicz
mesh_terms: D000328:Adult; D000380:Agranulocytosis / Q000209:etiology; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001365:Axilla; D064147:Febrile Neutropenia / Q000209:etiology*; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D000074324:Ipilimumab; D008207:Lymphatic Metastasis; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D009000:Monocytes / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D000074324:Ipilimumab